Cellectar Biosciences

OverviewSuggest Edit

Cellectar Biosciences is a clinical stage biopharmaceutical company that engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The Company offers product candidates for the treatment of relapse or refractory multiple myeloma, B-cell malignancies and micrometastatic disease, as well as for the treatment of chemotherapy. It also provides PDCs for the selective detection of tumors and metastases, and intraoperative tumor and tumor margin illumination.

TypePublic
Founded1996
HQMadison, US
Websitecellectar.com

Latest Updates

Employees (est.) (Dec 2018)7(-53%)
Share Price (Oct 2020)$1.2 (-2%)
Cybersecurity ratingAMore

Key People/Management at Cellectar Biosciences

James Caruso

James Caruso

President, CEO and Director
Fred Driscoll

Fred Driscoll

Director
John Friend

John Friend

Chief Medical Officer
John Neis

John Neis

Director
Jarrod Longcor

Jarrod Longcor

Chief Business Officer
Stefan D. Loren

Stefan D. Loren

Director
Show more

Cellectar Biosciences Office Locations

Cellectar Biosciences has offices in Madison and Florham Park
Madison, US (HQ)
3301 Agriculture Dr
Florham Park, US
100 Campus Dr #207
Show all (2)

Cellectar Biosciences Financials and Metrics

Cellectar Biosciences Revenue

USD

Net income (Q2, 2020)

(3.6m)

EBIT (Q2, 2020)

(3.6m)

Market capitalization (15-Oct-2020)

34.0m

Closing stock price (15-Oct-2020)

1.2

Cash (30-Jun-2020)

22.5m

EV

12.2m
Cellectar Biosciences's current market capitalization is $34 m.
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Cellectar Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Cellectar Biosciences Online and Social Media Presence

Embed Graph

Cellectar Biosciences News and Updates

Thinking about buying stock in Cellectar Biosciences, Cisco Systems, PDS Biotechnology, Uber, or Walmart?

NEW YORK, May 16, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLRB, CSCO, PDSB, UBER, and WMT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Cellectar Biosciences Announces $10.0 Million Financing

FLORHAM PARK, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered into definitive agreemen…

Cellectar Biosciences Frequently Asked Questions

  • When was Cellectar Biosciences founded?

    Cellectar Biosciences was founded in 1996.

  • Who are Cellectar Biosciences key executives?

    Cellectar Biosciences's key executives are James Caruso, Fred Driscoll and John Friend.

  • How many employees does Cellectar Biosciences have?

    Cellectar Biosciences has 7 employees.

  • Who are Cellectar Biosciences competitors?

    Competitors of Cellectar Biosciences include Therapeia, ImmunoCellular Therapeutics and Tetherex.

  • Where is Cellectar Biosciences headquarters?

    Cellectar Biosciences headquarters is located at 3301 Agriculture Dr, Madison.

  • Where are Cellectar Biosciences offices?

    Cellectar Biosciences has offices in Madison and Florham Park.

  • How many offices does Cellectar Biosciences have?

    Cellectar Biosciences has 2 offices.